Market Overview

Biogen Rallies On Tecfidera Patent Decision

Biogen Rallies On Tecfidera Patent Decision

Biogen Inc (NASDAQ: BIIB) shares were trading higher Wednesday following the issuing of a decision by the U.S. Patent and Trademark Office's Patent Trial and Appeal Board on a patent trial challenge by Mylan NV (NASDAQ: MYL) on '514 Tecfidera that was in Biogen's favor.

See Also: 9 Takeaways From The JPMorgan Healthcare Conference

Biogen’s top product is a multiple sclerosis drug, Tecfidera. Mylan had asked the U.S. Patent and Trademark Office to take a look at Biogen’s exclusive hold on Tecfidera until 2028, according to Barron’s.

Biogen shares were trading 24.62% higher at $353.04 at the time of publication, while Mylan shares were up 2.49% at $22.82.


Related Articles (BIIB + MYL)

View Comments and Join the Discussion!

Posted-In: Barron'sBiotech News Health Care Legal Movers Trading Ideas General Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at